The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine
Background: Increased understanding of the molecular causes of disease has begun to fulfill the promise of precision medicine with the development of targeted drugs, particularly for serious diseases with unmet needs. The drug approval regulatory process is a critical component to the continued grow...
Main Authors: | Ariel Kantor, Susanne B. Haga |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/11/1/45 |
Similar Items
-
Omaveloxolone approved for patients aged 16 years and older with Friedreich ataxia (FRDA): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
by: Arthur Lenahan, et al.
Published: (2023-01-01) -
Striking balance between expedited review and expecting efficacious anticancer drug and biologics: An ongoing challenge
by: Krishnan Vengadaragava Chary, et al.
Published: (2017-01-01) -
Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
by: Annemieke Aartsma-Rus, et al.
Published: (2021-12-01) -
Trends in orphan medicinal products approvals in the European Union between 2010–2022
by: Luísa Bouwman, et al.
Published: (2024-02-01) -
Investigating the landscape of US orphan product approvals
by: Kathleen L. Miller, et al.
Published: (2018-10-01)